Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.55 |
| ▸ | NPC1 | O15118 | 3/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | GLA | P06280 | 1/20 | 0.52 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | ALB | P02768 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22519155 | 0.89 | CYP1A2 (0.59) | RAB9ANPC1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL24616751 | 0.86 | PDE4A (0.48) | RAB9ANPC1KDM4EGAAMAPK1 | |
| SCHEMBL3499390 | 0.84 | SLC2A2 (0.58) | RAB9ANPC1KDM4ECYP1A2CYP2C9 | |
| SCHEMBL2251524 | 0.83 | RAB9A (0.55) | RAB9ANPC1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL9925354 | 0.83 | MAPT (0.45) | RAB9ANPC1KDM4EGAAKMT2A | |
| SCHEMBL9923914 | 0.81 | KDM4E (0.51) | RAB9ANPC1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL23387882 | 0.81 | PTGS1 (0.65) | RAB9AKDM4EALDH1A1SMN1; SMN2GAA | |
| SCHEMBL22519158 | 0.80 | RAB9A (0.52) | RAB9ANPC1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL29937800 | 0.80 | PTGS1 (0.42) | RAB9ANPC1KDM4EGAAMAPK1 | |
| SCHEMBL22519135 | 0.80 | NPC1 (0.56) | RAB9ANPC1KDM4EALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220217979-A1 | HETEROCYCLIC COMPOUND AND HARMFUL ARTHROPOD PEST CONTROL COMPOSITION CONTAINING SAME | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2022-07-14 | — | — | US | disclosed |
| US-9067935-B2 | Imidazo[1,2-α]pyridine sulfonamides as TRPM8 modulators | JANSSEN PHARMACEUTICA, NV (BE) | 2015-06-30 | — | — | US | disclosed |
| US-20140088098-A1 | IMIDAZO[1,2-a]PYRIDINE SULFONAMIDES AS TRPM8 MODULATORS | JANSSEN PHARMACEUTICA, NV (BE) | 2014-03-27 | — | — | US | disclosed |
| US-20120149699-A1 | IMIDAZO[1,2-a]PYRIDINE SULFONAMIDES AS TRPM8 MODULATORS | JANSSEN PHARMACEUTICA, NV (BE) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149699-A1 | IMIDAZO[1,2-a]PYRIDINE SULFONAMIDES AS TRPM8 MODULATORS | TRPM8, TRPV1, TRPM2 | RAB9A 661/4885NPC1 1267/4885KDM4E 3480/4885 |
| US-20140088098-A1 | IMIDAZO[1,2-a]PYRIDINE SULFONAMIDES AS TRPM8 MODULATORS | TRPM8, TRPV1, TRPM2 | RAB9A 661/4885NPC1 1267/4885KDM4E 3480/4885 |
| US-20220217979-A1 | HETEROCYCLIC COMPOUND AND HARMFUL ARTHROPOD PEST CONTROL COMPOSITION CONTAINING SAME | C5, COX6C, C1S | RAB9A 665/4885NPC1 2265/4885KDM4E 1825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.